Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

13.33
-0.4900-3.55%
Post-market: 13.430.1000+0.75%19:59 EDT
Volume:2.08M
Turnover:28.33M
Market Cap:1.84B
PE:-3.69
High:14.02
Open:13.82
Low:13.30
Close:13.82
52wk High:15.40
52wk Low:4.29
Shares:138.00M
Float Shares:107.00M
Volume Ratio:0.92
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:21.76
PE(LYR):-4.33

Loading ...

Evercore upgrades Compass Pathways to Outperform, views approval as likely

TIPRANKS
·
Jul 08

Why COMPASS Pathways (CMPS) Is Down 8.2% After New Phase 3 Data and Rolling NDA Update

Simply Wall St.
·
Jul 08

Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 Launch

TIPRANKS
·
Jul 08

Compass Pathways announces six-month data from COMP006 trial

TIPRANKS
·
Jul 08

Compass new data validates COMP360 durability profile, says Morgan Stanley

TIPRANKS
·
Jul 08

Compass Pathways is Maintained at Buy by BTIG

Dow Jones
·
Jul 08

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Tvardi Therapeutics (TVRD)

TIPRANKS
·
Jul 08

Compass Pathways data strengthens launch prospects, says Oppenheimer

TIPRANKS
·
Jul 07

Compass Pathways study data supports benefit of second dose, says Stifel

TIPRANKS
·
Jul 07

Compass Pathways Shares Down 5.4% After Co Reports Late-stage Trial Data for Depression Treatment

THOMSON REUTERS
·
Jul 07

Compass Pathways Publishes Investor Deck on Comp360 Psilocybin Therapy for Treatment-resistant Depression Approval Path

Reuters
·
Jul 07

U.S. Stocks on the Move-tesla, Nvidia, Rivian

Reuters
·
Jul 07

Compass Pathways Shares Gain on Positive Late-stage Trial Data for Depression Treatment

Dow Jones
·
Jul 07

Compass Pathways Shares up 8.6% Premarket After Positive Late-stage Trial Data for Depression Treatment

THOMSON REUTERS
·
Jul 07

Compass Pathways Says Phase 3 Comp006 Study Shows Comp360 Psilocybin Maintains Benefit Through Week 26 in TRD

Reuters
·
Jul 07

Compass Pathways - Comp360 Continues to Show Well-tolerated and Safe Profile with no New Safety Findings

THOMSON REUTERS
·
Jul 07

Compass Pathways Announces Six-month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

THOMSON REUTERS
·
Jul 07

Compass Pathways - Rolling Nda Submission Underway; Final Submission Expected in Q4

THOMSON REUTERS
·
Jul 07

Compass Pathways - Comp006 Phase 3 Trial Shows Durable Benefit Through 6 Months in Chronic Trd

THOMSON REUTERS
·
Jul 07

Compass Pathways - Commercial Launch of Comp360 Expected in First Half of 2027

THOMSON REUTERS
·
Jul 07